{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T09:54:17Z","timestamp":1768730057662,"version":"3.49.0"},"reference-count":157,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2023,11,14]],"date-time":"2023-11-14T00:00:00Z","timestamp":1699920000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,11,14]],"date-time":"2023-11-14T00:00:00Z","timestamp":1699920000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100012542","name":"Sichuan Province Science and Technology Support Program","doi-asserted-by":"publisher","award":["2021YFS0103"],"award-info":[{"award-number":["2021YFS0103"]}],"id":[{"id":"10.13039\/100012542","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Sci"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1007\/s10072-023-07172-2","type":"journal-article","created":{"date-parts":[[2023,11,14]],"date-time":"2023-11-14T08:02:49Z","timestamp":1699948969000},"page":"941-962","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Pharmacological treatment of Tourette\u2019s syndrome: from the past to the future"],"prefix":"10.1007","volume":"45","author":[{"given":"Hao","family":"Gong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiangyu","family":"Du","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anping","family":"Su","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9046-0278","authenticated-orcid":false,"given":"Yaowu","family":"Du","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,11,14]]},"reference":[{"issue":"12","key":"7172_CR1","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1038\/nrneurol.2011.167","volume":"7","author":"KS McNaught","year":"2011","unstructured":"McNaught KS, Mink JW (2011) Advances in understanding and treatment of Tourette syndrome. Nat Rev Neurol 7(12):667\u2013676","journal-title":"Nat Rev Neurol"},{"issue":"2","key":"7172_CR2","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1590\/S2317-17822013000200017","volume":"25","author":"DE Battle","year":"2013","unstructured":"Battle DE (2013) Diagnostic and statistical manual of mental disorders (DSM). Codas. 25(2):191\u2013192","journal-title":"Codas."},{"issue":"6","key":"7172_CR3","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/j.jpsychores.2009.07.010","volume":"67","author":"MM Robertson","year":"2009","unstructured":"Robertson MM, Eapen V, Cavanna AE (2009) The international prevalence, epidemiology, and clinical phenomenology of Tourette syndrome: a cross-cultural perspective. J Psychosom Res 67(6):475\u2013483","journal-title":"J Psychosom Res"},{"issue":"16","key":"7172_CR4","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1056\/NEJMra010032","volume":"345","author":"J Jankovic","year":"2001","unstructured":"Jankovic J (2001) Tourette\u2019s syndrome. N Engl J Med 345(16):1184\u20131192","journal-title":"N Engl J Med"},{"issue":"1 Pt 1","key":"7172_CR5","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1542\/peds.102.1.14","volume":"102","author":"JF Leckman","year":"1998","unstructured":"Leckman JF et al (1998) Course of tic severity in Tourette syndrome: the first two decades. Pediatrics 102(1 Pt 1):14\u201319","journal-title":"Pediatrics"},{"key":"7172_CR6","first-page":"7","volume":"58","author":"J Jankovic","year":"1992","unstructured":"Jankovic J (1992) Diagnosis and classification of tics and Tourette syndrome. Adv Neurol 58:7\u201314","journal-title":"Adv Neurol"},{"issue":"5","key":"7172_CR7","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1136\/archdischild-2011-300585","volume":"97","author":"MM Robertson","year":"2012","unstructured":"Robertson MM (2012) The Gilles de la Tourette syndrome: the current status. Arch Dis Child Educ Pract Ed 97(5):166\u2013175","journal-title":"Arch Dis Child Educ Pract Ed"},{"issue":"7","key":"7172_CR8","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1007\/s00415-003-1102-4","volume":"250","author":"A Berardelli","year":"2003","unstructured":"Berardelli A et al (2003) Pathophysiology of tics and Tourette syndrome. J Neurol 250(7):781\u2013787","journal-title":"J Neurol"},{"issue":"12","key":"7172_CR9","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.1212\/WNL.40.12.1837","volume":"40","author":"MY Neufeld","year":"1990","unstructured":"Neufeld MY et al (1990) Routine and quantitative EEG analysis in Gilles de la Tourette\u2019s syndrome. Neurology 40(12):1837\u20131839","journal-title":"Neurology"},{"issue":"2","key":"7172_CR10","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1177\/155005948801900212","volume":"19","author":"A Syrigou-Papavasiliou","year":"1988","unstructured":"Syrigou-Papavasiliou A, Verma NP, LeWitt PA (1988) Sensory evoked responses in Tourette syndrome. Clin Electroencephalogr 19(2):108\u2013110","journal-title":"Clin Electroencephalogr"},{"issue":"4","key":"7172_CR11","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1097\/WCO.0000000000000356","volume":"29","author":"C Ganos","year":"2016","unstructured":"Ganos C (2016) Tics and Tourette\u2019s: update on pathophysiology and tic control. Curr Opin Neurol 29(4):513\u2013518","journal-title":"Curr Opin Neurol"},{"issue":"4","key":"7172_CR12","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1097\/WCO.0000000000000575","volume":"31","author":"A Hartmann","year":"2018","unstructured":"Hartmann A, Worbe Y (2018) Tourette syndrome: clinical spectrum, mechanisms and personalized treatments. Curr Opin Neurol 31(4):504\u2013509","journal-title":"Curr Opin Neurol"},{"issue":"3","key":"7172_CR13","doi-asserted-by":"publisher","first-page":"e1005395","DOI":"10.1371\/journal.pcbi.1005395","volume":"13","author":"D Caligiore","year":"2017","unstructured":"Caligiore D et al (2017) Dysfunctions of the basal ganglia-cerebellar-thalamo-cortical system produce motor tics in Tourette syndrome. PLoS Comput Biol 13(3):e1005395","journal-title":"PLoS Comput Biol"},{"issue":"3","key":"7172_CR14","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1002\/cne.22206","volume":"518","author":"Y Kataoka","year":"2010","unstructured":"Kataoka Y et al (2010) Decreased number of parvalbumin and cholinergic interneurons in the striatum of individuals with Tourette syndrome. J Comp Neurol 518(3):277\u2013291","journal-title":"J Comp Neurol"},{"issue":"4","key":"7172_CR15","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1001\/archpsyc.60.4.415","volume":"60","author":"BS Peterson","year":"2003","unstructured":"Peterson BS et al (2003) Basal Ganglia volumes in patients with Gilles de la Tourette syndrome. Arch Gen Psychiatry 60(4):415\u2013424","journal-title":"Arch Gen Psychiatry"},{"issue":"5","key":"7172_CR16","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1212\/WNL.43.5.950","volume":"43","author":"HS Singer","year":"1993","unstructured":"Singer HS et al (1993) Volumetric MRI changes in basal ganglia of children with Tourette\u2019s syndrome. Neurology 43(5):950\u2013956","journal-title":"Neurology"},{"key":"7172_CR17","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.nicl.2013.11.011","volume":"4","author":"B Cheng","year":"2014","unstructured":"Cheng B et al (2014) Altered intrahemispheric structural connectivity in Gilles de la Tourette syndrome. Neuroimage Clin 4:174\u2013181","journal-title":"Neuroimage Clin"},{"issue":"Pt 2","key":"7172_CR18","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1093\/brain\/awu311","volume":"138","author":"Y Worbe","year":"2015","unstructured":"Worbe Y et al (2015) Altered structural connectivity of cortico-striato-pallido-thalamic networks in Gilles de la Tourette syndrome. Brain 138(Pt 2):472\u2013482","journal-title":"Brain"},{"issue":"1","key":"7172_CR19","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.pscychresns.2007.01.003","volume":"156","author":"CB Yeh","year":"2007","unstructured":"Yeh CB et al (2007) Phasic dysfunction of dopamine transmission in Tourette\u2019s syndrome evaluated with 99mTc TRODAT-1 imaging. Psychiatry Res 156(1):75\u201382","journal-title":"Psychiatry Res"},{"issue":"5","key":"7172_CR20","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/j.pedneo.2020.03.007","volume":"61","author":"CJ Hsu","year":"2020","unstructured":"Hsu CJ et al (2020) The multimodality neuroimage findings in individuals with Tourette syndrome. Pediatr Neonatol 61(5):467\u2013474","journal-title":"Pediatr Neonatol"},{"issue":"2","key":"7172_CR21","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1017\/S1461145706006559","volume":"10","author":"S Haugb\u00f8l","year":"2007","unstructured":"Haugb\u00f8l S et al (2007) Cerebral 5-HT2A receptor binding is increased in patients with Tourette\u2019s syndrome. Int J Neuropsychopharmacol 10(2):245\u2013252","journal-title":"Int J Neuropsychopharmacol"},{"key":"7172_CR22","first-page":"123","volume":"58","author":"GM Anderson","year":"1992","unstructured":"Anderson GM et al (1992) Postmortem analysis of subcortical monoamines and amino acids in Tourette syndrome. Adv Neurol 58:123\u2013133","journal-title":"Adv Neurol"},{"issue":"4","key":"7172_CR23","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1002\/ajmg.1320360410","volume":"36","author":"DE Comings","year":"1990","unstructured":"Comings DE (1990) Blood serotonin and tryptophan in Tourette syndrome. Am J Med Genet 36(4):418\u2013430","journal-title":"Am J Med Genet"},{"issue":"6","key":"7172_CR24","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/j.jpsychores.2009.06.006","volume":"67","author":"JA O'Rourke","year":"2009","unstructured":"O'Rourke JA et al (2009) The genetics of Tourette syndrome: a review. J Psychosom Res 67(6):533\u2013545","journal-title":"J Psychosom Res"},{"issue":"3","key":"7172_CR25","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1176\/appi.ajp.2018.18070857","volume":"176","author":"D Yu","year":"2019","unstructured":"Yu D et al (2019) Interrogating the genetic determinants of Tourette\u2019s syndrome and other tic disorders through genome-wide association studies. Am J Psychiatry 176(3):217\u2013227","journal-title":"Am J Psychiatry"},{"issue":"2","key":"7172_CR26","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1176\/ajp.155.2.264","volume":"155","author":"SE Swedo","year":"1998","unstructured":"Swedo SE et al (1998) Pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections: clinical description of the first 50 cases. Am J Psychiatry 155(2):264\u2013271","journal-title":"Am J Psychiatry"},{"issue":"10","key":"7172_CR27","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1111\/j.1469-8749.2011.04018.x","volume":"53","author":"D Martino","year":"2011","unstructured":"Martino D et al (2011) The relationship between group A streptococcal infections and Tourette syndrome: a study on a large service-based cohort. Dev Med Child Neurol 53(10):951\u2013957","journal-title":"Dev Med Child Neurol"},{"issue":"12","key":"7172_CR28","doi-asserted-by":"publisher","first-page":"e1680","DOI":"10.1212\/WNL.0000000000011610","volume":"96","author":"D Martino","year":"2021","unstructured":"Martino D et al (2021) Association of group A streptococcus exposure and exacerbations of chronic tic disorders: a multinational prospective cohort study. Neurology 96(12):e1680\u2013e1693","journal-title":"Neurology"},{"issue":"4","key":"7172_CR29","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1515\/JPM.1999.042","volume":"27","author":"L Burd","year":"1999","unstructured":"Burd L et al (1999) Prenatal and perinatal risk factors for Tourette disorder. J Perinat Med 27(4):295\u2013302","journal-title":"J Perinat Med"},{"issue":"5","key":"7172_CR30","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1038\/mp.2017.31","volume":"23","author":"G Brander","year":"2018","unstructured":"Brander G et al (2018) Perinatal risk factors in Tourette\u2019s and chronic tic disorders: a total population sibling comparison study. Mol Psychiatry 23(5):1189\u20131197","journal-title":"Mol Psychiatry"},{"key":"7172_CR31","doi-asserted-by":"crossref","unstructured":"Liu YC et al (2021) Association of prenatal maternal anemia with tics and Tourette\u2019s syndrome in offspring. J Pers Med 11(10)","DOI":"10.3390\/jpm11101038"},{"issue":"1","key":"7172_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.5468\/ogs.20252","volume":"64","author":"E Ayubi","year":"2021","unstructured":"Ayubi E, Mansori K, Doosti-Irani A (2021) Effect of maternal smoking during pregnancy on Tourette syndrome and chronic tic disorders among offspring: a systematic review and meta-analysis. Obstet Gynecol Sci 64(1):1\u201312","journal-title":"Obstet Gynecol Sci"},{"issue":"8","key":"7172_CR33","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1177\/08830738060210080401","volume":"21","author":"D Gilbert","year":"2006","unstructured":"Gilbert D (2006) Treatment of children and adolescents with tics and Tourette syndrome. J Child Neurol 21(8):690\u2013700","journal-title":"J Child Neurol"},{"issue":"19","key":"7172_CR34","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1212\/WNL.0000000000007467","volume":"92","author":"T Pringsheim","year":"2019","unstructured":"Pringsheim T et al (2019) Comprehensive systematic review summary: treatment of tics in people with Tourette syndrome and chronic tic disorders. Neurology 92(19):907\u2013915","journal-title":"Neurology"},{"issue":"19","key":"7172_CR35","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1212\/WNL.0000000000007466","volume":"92","author":"T Pringsheim","year":"2019","unstructured":"Pringsheim T et al (2019) Practice guideline recommendations summary: treatment of tics in people with Tourette syndrome and chronic tic disorders. Neurology 92(19):896\u2013906","journal-title":"Neurology"},{"issue":"5","key":"7172_CR36","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1007\/s00702-019-02105-w","volume":"127","author":"J Jankovic","year":"2020","unstructured":"Jankovic J (2020) Treatment of tics associated with Tourette syndrome. J Neural Transm (Vienna) 127(5):843\u2013850","journal-title":"J Neural Transm (Vienna)"},{"issue":"3","key":"7172_CR37","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1001\/jamaneurol.2017.4317","volume":"75","author":"D Martinez-Ramirez","year":"2018","unstructured":"Martinez-Ramirez D et al (2018) Efficacy and safety of deep brain stimulation in Tourette syndrome: the international Tourette syndrome deep brain stimulation public database and registry. JAMA Neurol 75(3):353\u2013359","journal-title":"JAMA Neurol"},{"issue":"6","key":"7172_CR38","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/S1474-4422(15)00008-3","volume":"14","author":"Z Kefalopoulou","year":"2015","unstructured":"Kefalopoulou Z et al (2015) Bilateral globus pallidus stimulation for severe Tourette\u2019s syndrome: a double-blind, randomised crossover trial. Lancet Neurol 14(6):595\u2013605","journal-title":"Lancet Neurol"},{"issue":"1","key":"7172_CR39","first-page":"578","volume":"119","author":"JN Seignot","year":"1961","unstructured":"Seignot JN (1961) A case of tic of Gilles de la Tourette cured by R 1625. Ann Med Psychol (Paris) 119(1):578\u2013579","journal-title":"Ann Med Psychol (Paris)"},{"issue":"5","key":"7172_CR40","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1176\/ajp.135.5.585","volume":"135","author":"MS Ross","year":"1978","unstructured":"Ross MS, Moldofsky H (1978) A comparison of pimozide and haloperidol in the treatment of Gilles de la Tourette\u2019s syndrome. Am J Psychiatry 135(5):585\u2013587","journal-title":"Am J Psychiatry"},{"issue":"8","key":"7172_CR41","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1001\/archpsyc.1989.01810080052006","volume":"46","author":"E Shapiro","year":"1989","unstructured":"Shapiro E et al (1989) Controlled study of haloperidol, pimozide and placebo for the treatment of Gilles de la Tourette\u2019s syndrome. Arch Gen Psychiatry 46(8):722\u2013730","journal-title":"Arch Gen Psychiatry"},{"issue":"4","key":"7172_CR42","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/s00787-011-0163-7","volume":"20","author":"V Roessner","year":"2011","unstructured":"Roessner V et al (2011) European clinical guidelines for Tourette syndrome and other tic disorders. Part II: pharmacological treatment. Eur Child Adolesc Psychiatry 20(4):173\u2013196","journal-title":"Eur Child Adolesc Psychiatry"},{"issue":"8","key":"7172_CR43","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1176\/ajp.154.8.1057","volume":"154","author":"FR Sallee","year":"1997","unstructured":"Sallee FR et al (1997) Relative efficacy of haloperidol and pimozide in children and adolescents with Tourette\u2019s disorder. Am J Psychiatry 154(8):1057\u20131062","journal-title":"Am J Psychiatry"},{"key":"7172_CR44","first-page":"391","volume":"35","author":"JF Leckman","year":"1982","unstructured":"Leckman JF et al (1982) Clonidine in the treatment of Tourette syndrome: a review of data. Adv Neurol 35:391\u2013401","journal-title":"Adv Neurol"},{"issue":"12","key":"7172_CR45","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1001\/archpsyc.1980.01780250036004","volume":"37","author":"DJ Cohen","year":"1980","unstructured":"Cohen DJ et al (1980) Clonidine ameliorates Gilles de la Tourette syndrome. Arch Gen Psychiatry 37(12):1350\u20131357","journal-title":"Arch Gen Psychiatry"},{"issue":"5","key":"7172_CR46","first-page":"328","volume":"30","author":"CV Ford","year":"1969","unstructured":"Ford CV, Gottlieb F (1969) An objective evaluation of haloperidol in Gilles de la Tourette\u2019s syndrome. Dis Nerv Syst 30(5):328\u2013332","journal-title":"Dis Nerv Syst"},{"issue":"3","key":"7172_CR47","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1002\/ana.410220317","volume":"22","author":"G Erenberg","year":"1987","unstructured":"Erenberg G, Cruse RP, Rothner AD (1987) The natural history of Tourette syndrome: a follow-up study. Ann Neurol 22(3):383\u2013385","journal-title":"Ann Neurol"},{"issue":"8002","key":"7172_CR48","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/S0140-6736(77)91126-6","volume":"1","author":"MS Rose","year":"1977","unstructured":"Rose MS, Moldofsky H (1977) Comparison of pimozide with haloperidol in Gilles de la Tourette syndrome. Lancet 1(8002):103","journal-title":"Lancet"},{"issue":"10","key":"7172_CR49","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1016\/0006-3223(95)00596-X","volume":"40","author":"FR Sallee","year":"1996","unstructured":"Sallee FR et al (1996) Prolactin monitoring of haloperidol and pimozide treatment in children with Tourette\u2019s syndrome. Biol Psychiatry 40(10):1044\u20131050","journal-title":"Biol Psychiatry"},{"issue":"2","key":"7172_CR50","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1097\/00004583-200402000-00017","volume":"43","author":"DL Gilbert","year":"2004","unstructured":"Gilbert DL et al (2004) Tic reduction with risperidone versus pimozide in a randomized, double-blind, crossover trial. J Am Acad Child Adolesc Psychiatry 43(2):206\u2013214","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"7172_CR51","first-page":"CD006352","volume":"6","author":"HE Matar","year":"2018","unstructured":"Matar HE, Almerie MQ, Sampson SJ (2018) Fluphenazine (oral) versus placebo for schizophrenia. Cochrane Database Syst Rev 6:CD006352","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"7172_CR52","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/0361-9230(83)90192-2","volume":"11","author":"RL Borison","year":"1983","unstructured":"Borison RL et al (1983) Treatment approaches in Gilles de la Tourette syndrome. Brain Res Bull 11(2):205\u2013208","journal-title":"Brain Res Bull"},{"issue":"3","key":"7172_CR53","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1001\/archneur.1984.04050150049015","volume":"41","author":"CG Goetz","year":"1984","unstructured":"Goetz CG, Tanner CM, Klawans HL (1984) Fluphenazine and multifocal tic disorders. Arch Neurol 41(3):271\u2013272","journal-title":"Arch Neurol"},{"issue":"2","key":"7172_CR54","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1089\/1044546041648959","volume":"14","author":"RJ Stephens","year":"2004","unstructured":"Stephens RJ, Bassel C, Sandor P (2004) Olanzapine in the treatment of aggression and tics in children with Tourette\u2019s syndrome--a pilot study. J Child Adolesc Psychopharmacol 14(2):255\u2013266","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"2","key":"7172_CR55","first-page":"685","volume":"244","author":"PA Janssen","year":"1988","unstructured":"Janssen PA et al (1988) Pharmacology of risperidone (R 64 766), a new antipsychotic with serotonin-S2 and dopamine-D2 antagonistic properties. J Pharmacol Exp Ther 244(2):685\u2013693","journal-title":"J Pharmacol Exp Ther"},{"issue":"2","key":"7172_CR56","first-page":"661","volume":"247","author":"JE Leysen","year":"1988","unstructured":"Leysen JE et al (1988) Biochemical profile of risperidone, a new antipsychotic. J Pharmacol Exp Ther 247(2):661\u2013670","journal-title":"J Pharmacol Exp Ther"},{"issue":"8936","key":"7172_CR57","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1016\/S0140-6736(94)90389-1","volume":"344","author":"M Stamenkovic","year":"1994","unstructured":"Stamenkovic M, Aschauer H, Kasper S (1994) Risperidone for Tourette\u2019s syndrome. Lancet 344(8936):1577\u20131578","journal-title":"Lancet"},{"key":"7172_CR58","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.neuropharm.2012.05.043","volume":"68","author":"V Roessner","year":"2013","unstructured":"Roessner V et al (2013) Pharmacological treatment of tic disorders and Tourette syndrome. Neuropharmacology 68:143\u2013149","journal-title":"Neuropharmacology"},{"issue":"1","key":"7172_CR59","doi-asserted-by":"publisher","first-page":"50","DOI":"10.4088\/JCP.v62n0111","volume":"62","author":"R Bruggeman","year":"2001","unstructured":"Bruggeman R et al (2001) Risperidone versus pimozide in Tourette\u2019s disorder: a comparative double-blind parallel-group study. J Clin Psychiatry 62(1):50\u201356","journal-title":"J Clin Psychiatry"},{"issue":"1","key":"7172_CR60","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1097\/00004714-200202000-00006","volume":"22","author":"Y Dion","year":"2002","unstructured":"Dion Y et al (2002) Risperidone in the treatment of tourette syndrome: a double-blind, placebo-controlled trial. J Clin Psychopharmacol 22(1):31\u201339","journal-title":"J Clin Psychopharmacol"},{"issue":"7","key":"7172_CR61","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1212\/01.WNL.0000055434.39968.67","volume":"60","author":"L Scahill","year":"2003","unstructured":"Scahill L et al (2003) A placebo-controlled trial of risperidone in Tourette syndrome. Neurology 60(7):1130\u20131135","journal-title":"Neurology"},{"issue":"2","key":"7172_CR62","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1089\/cap.1998.8.107","volume":"8","author":"J Krishnamoorthy","year":"1998","unstructured":"Krishnamoorthy J, King BH (1998) Open-label olanzapine treatment in five preadolescent children. J Child Adolesc Psychopharmacol 8(2):107\u2013113","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"7172_CR63","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.pnpbp.2013.08.005","volume":"47","author":"J Lian","year":"2013","unstructured":"Lian J et al (2013) Effects of olanzapine and betahistine co-treatment on serotonin transporter, 5-HT2A and dopamine D2 receptor binding density. Prog Neuropsychopharmacol Biol Psychiatry 47:62\u201368","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"6","key":"7172_CR64","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1007\/s004150070173","volume":"247","author":"M Onofrj","year":"2000","unstructured":"Onofrj M et al (2000) Olanzapine in severe Gilles de la Tourette syndrome: a 52-week double-blind cross-over study vs. low-dose pimozide. J Neurol 247(6):443\u2013446","journal-title":"J Neurol"},{"issue":"1","key":"7172_CR65","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1097\/00004850-200015010-00003","volume":"15","author":"M Stamenkovic","year":"2000","unstructured":"Stamenkovic M et al (2000) Effective open-label treatment of Tourette\u2019s disorder with olanzapine. Int Clin Psychopharmacol 15(1):23\u201328","journal-title":"Int Clin Psychopharmacol"},{"issue":"4","key":"7172_CR66","doi-asserted-by":"publisher","first-page":"290","DOI":"10.4088\/JCP.v62n0412","volume":"62","author":"CL Budman","year":"2001","unstructured":"Budman CL et al (2001) An open-label study of the treatment efficacy of olanzapine for Tourette\u2019s disorder. J Clin Psychiatry 62(4):290\u2013294","journal-title":"J Clin Psychiatry"},{"issue":"6","key":"7172_CR67","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1517\/14656566.2.6.1033","volume":"2","author":"PE Keck Jr","year":"2001","unstructured":"Keck PE Jr, McElroy SL, Arnold LM (2001) Ziprasidone: a new atypical antipsychotic. Expert Opin Pharmacother 2(6):1033\u20131042","journal-title":"Expert Opin Pharmacother"},{"issue":"3","key":"7172_CR68","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1097\/00004583-200003000-00010","volume":"39","author":"FR Sallee","year":"2000","unstructured":"Sallee FR et al (2000) Ziprasidone treatment of children and adolescents with Tourette\u2019s syndrome: a pilot study. J Am Acad Child Adolesc Psychiatry 39(3):292\u2013299","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"2","key":"7172_CR69","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1007\/s40272-015-0119-3","volume":"17","author":"G Masi","year":"2015","unstructured":"Masi G et al (2015) Use of quetiapine in children and adolescents. Paediatr Drugs 17(2):125\u2013140","journal-title":"Paediatr Drugs"},{"issue":"2","key":"7172_CR70","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1089\/104454601750284108","volume":"11","author":"HC P\u00e1rraga","year":"2001","unstructured":"P\u00e1rraga HC et al (2001) Quetiapine treatment of children with Tourette\u2019s syndrome: report of two cases. J Child Adolesc Psychopharmacol 11(2):187\u2013191","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"3","key":"7172_CR71","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1089\/104454603322572624","volume":"13","author":"NM Mukaddes","year":"2003","unstructured":"Mukaddes NM, Abali O (2003) Quetiapine treatment of children and adolescents with Tourette\u2019s disorder. J Child Adolesc Psychopharmacol 13(3):295\u2013299","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"7","key":"7172_CR72","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.4088\/JCP.v68n0726e","volume":"68","author":"JL de Jonge","year":"2007","unstructured":"de Jonge JL, Cath DC, van Balkom AJ (2007) Quetiapine in patients with Tourette\u2019s disorder: an open-label, flexible-dose study. J Clin Psychiatry 68(7):1148\u20131150","journal-title":"J Clin Psychiatry"},{"issue":"5","key":"7172_CR73","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1080\/14656566.2020.1721465","volume":"21","author":"N Cothros","year":"2020","unstructured":"Cothros N, Medina A, Pringsheim T (2020) Current pharmacotherapy for tic disorders. Expert Opin Pharmacother 21(5):567\u2013580","journal-title":"Expert Opin Pharmacother"},{"issue":"8","key":"7172_CR74","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1038\/sj.npp.1300203","volume":"28","author":"DA Shapiro","year":"2003","unstructured":"Shapiro DA et al (2003) Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology 28(8):1400\u20131411","journal-title":"Neuropsychopharmacology"},{"issue":"3","key":"7172_CR75","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1590\/S1516-44462004000300015","volume":"26","author":"A Hounie","year":"2004","unstructured":"Hounie A et al (2004) Aripiprazole and Tourette syndrome. Braz J Psychiatry 26(3):213","journal-title":"Braz J Psychiatry"},{"issue":"3","key":"7172_CR76","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/s00787-010-0154-0","volume":"20","author":"HK Yoo","year":"2010","unstructured":"Yoo HK et al (2010) Open-label study comparing the efficacy and tolerability of aripiprazole and haloperidol in the treatment of pediatric tic disorders. European Child & Adolescent Psychiatry 20(3):127\u2013135","journal-title":"European Child & Adolescent Psychiatry"},{"issue":"8","key":"7172_CR77","doi-asserted-by":"publisher","first-page":"e772","DOI":"10.4088\/JCP.12m08189","volume":"74","author":"HK Yoo","year":"2013","unstructured":"Yoo HK et al (2013) A multicenter, randomized, double-blind, placebo-controlled study of aripiprazole in children and adolescents with Tourette\u2019s disorder. J Clin Psychiatry 74(8):e772\u2013e780","journal-title":"J Clin Psychiatry"},{"issue":"9","key":"7172_CR78","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1089\/cap.2016.0026","volume":"27","author":"F Sallee","year":"2017","unstructured":"Sallee F et al (2017) Randomized, double-blind, placebo-controlled trial demonstrates the efficacy and safety of oral Aripiprazole for the treatment of Tourette\u2019s disorder in children and adolescents. J Child Adolesc Psychopharmacol 27(9):771\u2013781","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"3","key":"7172_CR79","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1177\/070674371205700302","volume":"57","author":"T Pringsheim","year":"2012","unstructured":"Pringsheim T et al (2012) Canadian guidelines for the evidence-based treatment of tic disorders: pharmacotherapy. Can J Psychiatry 57(3):133\u2013143","journal-title":"Can J Psychiatry"},{"issue":"8142","key":"7172_CR80","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/S0140-6736(79)91614-3","volume":"2","author":"DJ Cohen","year":"1979","unstructured":"Cohen DJ et al (1979) Clonidine in Tourette\u2019s syndrome. Lancet 2(8142):551\u2013553","journal-title":"Lancet"},{"issue":"8200","key":"7172_CR81","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1016\/S0140-6736(80)92094-2","volume":"2","author":"MW Dysken","year":"1980","unstructured":"Dysken MW et al (1980) Clonidine in Tourette syndrome. Lancet 2(8200):926\u2013927","journal-title":"Lancet"},{"issue":"11","key":"7172_CR82","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1001\/archpsyc.1983.01790100081011","volume":"40","author":"AK Shapiro","year":"1983","unstructured":"Shapiro AK, Shapiro E, Eisenkraft GJ (1983) Treatment of Gilles de la Tourette\u2019s syndrome with clonidine and neuroleptics. Arch Gen Psychiatry 40(11):1235\u20131240","journal-title":"Arch Gen Psychiatry"},{"issue":"3","key":"7172_CR83","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1002\/ana.410210313","volume":"21","author":"CG Goetz","year":"1987","unstructured":"Goetz CG et al (1987) Clonidine and Gilles de la Tourette\u2019s syndrome: double-blind study using objective rating methods. Ann Neurol 21(3):307\u2013310","journal-title":"Ann Neurol"},{"issue":"4","key":"7172_CR84","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1001\/archpsyc.1991.01810280040006","volume":"48","author":"JF Leckman","year":"1991","unstructured":"Leckman JF et al (1991) Clonidine treatment of Gilles de la Tourette\u2019s syndrome. Arch Gen Psychiatry 48(4):324\u2013328","journal-title":"Arch Gen Psychiatry"},{"issue":"1","key":"7172_CR85","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1542\/peds.95.1.74","volume":"95","author":"HS Singer","year":"1995","unstructured":"Singer HS et al (1995) The treatment of attention-deficit hyperactivity disorder in Tourette\u2019s syndrome: a double-blind placebo-controlled study with clonidine and desipramine. Pediatrics 95(1):74\u201381","journal-title":"Pediatrics"},{"issue":"4","key":"7172_CR86","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1212\/WNL.58.4.527","volume":"58","author":"T.s.S.S.","year":"2002","unstructured":"Group, T.s.S.S. (2002) Treatment of ADHD in children with tics: a randomized controlled trial. Neurology 58(4):527\u2013536","journal-title":"Neurology"},{"issue":"9","key":"7172_CR87","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1080\/00048670802277222","volume":"42","author":"YS Du","year":"2008","unstructured":"Du YS et al (2008) Randomized double-blind multicentre placebo-controlled clinical trial of the clonidine adhesive patch for the treatment of tic disorders. Aust N Z J Psychiatry 42(9):807\u2013813","journal-title":"Aust N Z J Psychiatry"},{"issue":"1","key":"7172_CR88","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.ejpn.2015.10.002","volume":"20","author":"F Jiao","year":"2016","unstructured":"Jiao F et al (2016) Clinical observation on treatment of Tourette syndrome in Chinese children by clonidine adhesive patch. Eur J Paediatr Neurol 20(1):80\u201384","journal-title":"Eur J Paediatr Neurol"},{"issue":"6","key":"7172_CR89","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1097\/00002826-200211000-00009","volume":"25","author":"DD Cummings","year":"2002","unstructured":"Cummings DD et al (2002) Neuropsychiatric effects of guanfacine in children with mild Tourette syndrome: a pilot study. Clin Neuropharmacol 25(6):325\u2013332","journal-title":"Clin Neuropharmacol"},{"issue":"9","key":"7172_CR90","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1097\/00004583-199509000-00010","volume":"34","author":"PB Chappell","year":"1995","unstructured":"Chappell PB et al (1995) Guanfacine treatment of comorbid attention-deficit hyperactivity disorder and Tourette\u2019s syndrome: preliminary clinical experience. J Am Acad Child Adolesc Psychiatry 34(9):1140\u20131146","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"9","key":"7172_CR91","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1089\/cap.2017.0024","volume":"27","author":"TK Murphy","year":"2017","unstructured":"Murphy TK et al (2017) Extended-release guanfacine does not show a large effect on tic severity in children with chronic tic disorders. J Child Adolesc Psychopharmacol 27(9):762\u2013770","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"3","key":"7172_CR92","doi-asserted-by":"publisher","first-page":"203","DOI":"10.2165\/00148581-200911030-00005","volume":"11","author":"KP Garnock-Jones","year":"2009","unstructured":"Garnock-Jones KP, Keating GM (2009) Atomoxetine: a review of its use in attention-deficit hyperactivity disorder in children and adolescents. Paediatr Drugs 11(3):203\u2013226","journal-title":"Paediatr Drugs"},{"issue":"12","key":"7172_CR93","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1212\/01.wnl.0000188869.58300.a7","volume":"65","author":"AJ Allen","year":"2005","unstructured":"Allen AJ et al (2005) Atomoxetine treatment in children and adolescents with ADHD and comorbid tic disorders. Neurology 65(12):1941\u20131949","journal-title":"Neurology"},{"issue":"4","key":"7172_CR94","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1177\/1087054707306109","volume":"11","author":"TJ Spencer","year":"2008","unstructured":"Spencer TJ et al (2008) Atomoxetine treatment of ADHD in children with comorbid Tourette syndrome. J Atten Disord 11(4):470\u2013481","journal-title":"J Atten Disord"},{"issue":"3","key":"7172_CR95","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1002\/ana.410050316","volume":"5","author":"ED Caine","year":"1979","unstructured":"Caine ED et al (1979) Trial of chlorimipramine and desipramine for Gilles de la Tourette syndrome. Ann Neurol 5(3):305\u2013306","journal-title":"Ann Neurol"},{"issue":"7","key":"7172_CR96","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1001\/archpsyc.59.7.649","volume":"59","author":"T Spencer","year":"2002","unstructured":"Spencer T et al (2002) A double-blind comparison of desipramine and placebo in children and adolescents with chronic tic disorder and comorbid attention-deficit\/hyperactivity disorder. Arch Gen Psychiatry 59(7):649\u2013656","journal-title":"Arch Gen Psychiatry"},{"issue":"1","key":"7172_CR97","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s40263-017-0486-0","volume":"32","author":"J Quezada","year":"2018","unstructured":"Quezada J, Coffman KA (2018) Current approaches and new developments in the pharmacological management of Tourette syndrome. CNS Drugs 32(1):33\u201345","journal-title":"CNS Drugs"},{"issue":"6","key":"7172_CR98","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1176\/appi.ajp.158.6.968","volume":"158","author":"FS Abuzzahab","year":"2001","unstructured":"Abuzzahab FS, Brown VL (2001) Control of Tourette\u2019s syndrome with topiramate. Am J Psychiatry 158(6):968","journal-title":"Am J Psychiatry"},{"issue":"1","key":"7172_CR99","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1136\/jnnp.2009.185348","volume":"81","author":"J Jankovic","year":"2010","unstructured":"Jankovic J, Jimenez-Shahed J, Brown LW (2010) A randomised, double-blind, placebo-controlled study of topiramate in the treatment of Tourette syndrome. J Neurol Neurosurg Psychiatry 81(1):70\u201373","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"5","key":"7172_CR100","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1038\/sj.bjp.0704766","volume":"136","author":"JM Rigo","year":"2002","unstructured":"Rigo JM et al (2002) The anti-epileptic drug levetiracetam reverses the inhibition by negative allosteric modulators of neuronal GABA- and glycine-gated currents. Br J Pharmacol 136(5):659\u2013672","journal-title":"Br J Pharmacol"},{"issue":"6","key":"7172_CR101","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1002\/mds.20385","volume":"20","author":"Y Awaad","year":"2005","unstructured":"Awaad Y, Michon AM, Minarik S (2005) Use of levetiracetam to treat tics in children and adolescents with Tourette syndrome. Mov Disord 20(6):714\u2013718","journal-title":"Mov Disord"},{"issue":"12","key":"7172_CR102","doi-asserted-by":"publisher","first-page":"1764","DOI":"10.1002\/mds.21615","volume":"22","author":"CL Smith-Hicks","year":"2007","unstructured":"Smith-Hicks CL et al (2007) A double blind randomized placebo control trial of levetiracetam in Tourette syndrome. Mov Disord 22(12):1764\u20131770","journal-title":"Mov Disord"},{"issue":"6","key":"7172_CR103","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/j.pediatrneurol.2008.12.014","volume":"40","author":"EF Hedderick","year":"2009","unstructured":"Hedderick EF, Morris CM, Singer HS (2009) Double-blind, crossover study of clonidine and levetiracetam in Tourette syndrome. Pediatr Neurol 40(6):420\u2013425","journal-title":"Pediatr Neurol"},{"issue":"2","key":"7172_CR104","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1007\/s10072-005-0448-z","volume":"26","author":"C Cianchetti","year":"2005","unstructured":"Cianchetti C et al (2005) Pergolide improvement in neuroleptic-resistant Tourette cases: various mechanisms causing tics. Neurological Sciences 26(2):137\u2013139","journal-title":"Neurological Sciences"},{"issue":"9","key":"7172_CR105","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1001\/archpsyc.1979.01780090065007","volume":"36","author":"M Feinberg","year":"1979","unstructured":"Feinberg M, Carroll BJ (1979) Effects of dopamine agonists and antagonists in Tourette\u2019s disease. Arch Gen Psychiatry 36(9):979\u2013985","journal-title":"Arch Gen Psychiatry"},{"issue":"3","key":"7172_CR106","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1002\/mds.870120320","volume":"12","author":"JF Lipinski","year":"1997","unstructured":"Lipinski JF et al (1997) Dopamine agonist treatment of Tourette disorder in children: results of an open-label trial of pergolide. Mov Disord 12(3):402\u2013407","journal-title":"Mov Disord"},{"issue":"6","key":"7172_CR107","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1212\/WNL.54.6.1310","volume":"54","author":"DL Gilbert","year":"2000","unstructured":"Gilbert DL et al (2000) Tourette\u2019s syndrome improvement with pergolide in a randomized, double-blind, crossover trial. Neurology 54(6):1310\u20131315","journal-title":"Neurology"},{"issue":"4","key":"7172_CR108","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1212\/01.WNL.0000044058.64647.7E","volume":"60","author":"DL Gilbert","year":"2003","unstructured":"Gilbert DL et al (2003) Tic reduction with pergolide in a randomized controlled trial in children. Neurology 60(4):606\u2013611","journal-title":"Neurology"},{"issue":"6","key":"7172_CR109","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1007\/s11940-010-0095-4","volume":"12","author":"HS Singer","year":"2010","unstructured":"Singer HS (2010) Treatment of tics and tourette syndrome. Curr Treat Options Neurol 12(6):539\u2013561","journal-title":"Curr Treat Options Neurol"},{"issue":"10","key":"7172_CR110","first-page":"723","volume":"19","author":"AF Shaughnessy","year":"1985","unstructured":"Shaughnessy AF (1985) Potential uses for metoclopramide. Drug Intell Clin Pharm 19(10):723\u2013728","journal-title":"Drug Intell Clin Pharm"},{"issue":"3","key":"7172_CR111","first-page":"181","volume":"29","author":"AB Desai","year":"1983","unstructured":"Desai AB, Doongaji DR, Satoskar RS (1983) Metoclopramide in Gilles de la Tourette\u2019s syndrome (a case report). J Postgrad Med 29(3):181\u2013183","journal-title":"J Postgrad Med"},{"issue":"7","key":"7172_CR112","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1097\/01.chi.0000163279.39598.44","volume":"44","author":"R Nicolson","year":"2005","unstructured":"Nicolson R et al (2005) A randomized, double-blind, placebo-controlled trial of metoclopramide for the treatment of Tourette\u2019s disorder. J Am Acad Child Adolesc Psychiatry 44(7):640\u2013646","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"5","key":"7172_CR113","doi-asserted-by":"publisher","first-page":"460","DOI":"10.2165\/00002512-199303050-00007","volume":"3","author":"JW Steele","year":"1993","unstructured":"Steele JW, Faulds D, Sorkin EM, Tiapride. (1993) A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in geriatric agitation. Drugs Aging 3(5):460\u2013478","journal-title":"Drugs Aging"},{"issue":"4","key":"7172_CR114","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1007\/BF00449911","volume":"237","author":"C Eggers","year":"1988","unstructured":"Eggers C, Rothenberger A, Berghaus U (1988) Clinical and neurobiological findings in children suffering from tic disease following treatment with tiapride. Eur Arch Psychiatry Neurol Sci 237(4):223\u2013229","journal-title":"Eur Arch Psychiatry Neurol Sci"},{"key":"7172_CR115","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/B978-0-12-411546-0.00010-X","volume":"112","author":"S Mogwitz","year":"2013","unstructured":"Mogwitz S et al (2013) Clinical pharmacology of dopamine-modulating agents in Tourette\u2019s syndrome. Int Rev Neurobiol 112:281\u2013349","journal-title":"Int Rev Neurobiol"},{"issue":"3","key":"7172_CR116","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1097\/00002826-199006000-00005","volume":"13","author":"MM Robertson","year":"1990","unstructured":"Robertson MM, Schnieden V, Lees AJ (1990) Management of Gilles de la Tourette syndrome using sulpiride. Clin Neuropharmacol 13(3):229\u2013235","journal-title":"Clin Neuropharmacol"},{"issue":"10","key":"7172_CR117","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1016\/S0929-6646(09)60406-X","volume":"108","author":"CS Ho","year":"2009","unstructured":"Ho CS et al (2009) Short-term sulpiride treatment of children and adolescents with Tourette syndrome or chronic tic disorder. J Formos Med Assoc 108(10):788\u2013793","journal-title":"J Formos Med Assoc"},{"issue":"Pt 3","key":"7172_CR118","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1093\/brain\/123.3.425","volume":"123","author":"MM Robertson","year":"2000","unstructured":"Robertson MM (2000) Tourette syndrome, associated conditions and the complexities of treatment. Brain 123(Pt 3):425\u2013462","journal-title":"Brain"},{"issue":"1","key":"7172_CR119","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1177\/1756285610390261","volume":"4","author":"CM Eddy","year":"2011","unstructured":"Eddy CM, Rickards HE, Cavanna AE (2011) Treatment strategies for tics in Tourette syndrome. Ther Adv Neurol Disord 4(1):25\u201345","journal-title":"Ther Adv Neurol Disord"},{"issue":"2","key":"7172_CR120","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1111\/j.1527-3458.2001.tb00195.x","volume":"7","author":"JH Ye","year":"2001","unstructured":"Ye JH, Ponnudurai R, Schaefer R (2001) Ondansetron: a selective 5-HT(3) receptor antagonist and its applications in CNS-related disorders. CNS Drug Rev 7(2):199\u2013213","journal-title":"CNS Drug Rev"},{"issue":"6","key":"7172_CR121","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1097\/00004850-199911000-00008","volume":"14","author":"P Toren","year":"1999","unstructured":"Toren P et al (1999) Ondansetron treatment in patients with Tourette\u2019s syndrome. Int Clin Psychopharmacol 14(6):373\u2013376","journal-title":"Int Clin Psychopharmacol"},{"issue":"4","key":"7172_CR122","doi-asserted-by":"publisher","first-page":"499","DOI":"10.4088\/JCP.v66n0413","volume":"66","author":"P Toren","year":"2005","unstructured":"Toren P et al (2005) Ondansetron treatment in Tourette\u2019s disorder: a 3-week, randomized, double-blind, placebo-controlled study. J Clin Psychiatry 66(4):499\u2013503","journal-title":"J Clin Psychiatry"},{"issue":"5","key":"7172_CR123","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1177\/088307389901400508","volume":"14","author":"Y Awaad","year":"1999","unstructured":"Awaad Y (1999) Tics in Tourette syndrome: new treatment options. J Child Neurol 14(5):316\u2013319","journal-title":"J Child Neurol"},{"issue":"5","key":"7172_CR124","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1212\/WNL.56.5.599","volume":"56","author":"HS Singer","year":"2001","unstructured":"Singer HS et al (2001) Baclofen treatment in Tourette syndrome: a double-blind, placebo-controlled, crossover trial. Neurology 56(5):599\u2013604","journal-title":"Neurology"},{"key":"7172_CR125","first-page":"277","volume":"37","author":"J Jankovic","year":"1983","unstructured":"Jankovic J (1983) Tetrabenazine in the treatment of hyperkinetic movement disorders. Adv Neurol 37:277\u2013289","journal-title":"Adv Neurol"},{"issue":"17","key":"7172_CR126","doi-asserted-by":"publisher","first-page":"2883","DOI":"10.1517\/14656560903386292","volume":"10","author":"A Fasano","year":"2009","unstructured":"Fasano A, Bentivoglio AR (2009) Tetrabenazine. Expert Opin Pharmacother 10(17):2883\u20132896","journal-title":"Expert Opin Pharmacother"},{"issue":"6","key":"7172_CR127","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1001\/archpsyc.1974.01760180095012","volume":"31","author":"RD Sweet","year":"1974","unstructured":"Sweet RD et al (1974) Presynaptic catecholamine antagonists as treatment for Tourette syndrome. Effects of alpha methyl para tyrosine and tetrabenazine. Arch Gen Psychiatry 31(6):857\u2013861","journal-title":"Arch Gen Psychiatry"},{"issue":"5","key":"7172_CR128","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1212\/WNL.34.5.688","volume":"34","author":"J Jankovic","year":"1984","unstructured":"Jankovic J, Glaze DG, Frost JD Jr (1984) Effect of tetrabenazine on tics and sleep of Gilles de la Tourette\u2019s syndrome. Neurology 34(5):688\u2013692","journal-title":"Neurology"},{"key":"7172_CR129","doi-asserted-by":"publisher","first-page":"422","DOI":"10.5334\/tohm.287","volume":"6","author":"J Jankovic","year":"2016","unstructured":"Jankovic J et al (2016) Deutetrabenazine in tics associated with Tourette syndrome. Tremor Other Hyperkinet Mov (N Y) 6:422","journal-title":"Tremor Other Hyperkinet Mov (N Y)"},{"issue":"10","key":"7172_CR130","doi-asserted-by":"publisher","first-page":"e2128204","DOI":"10.1001\/jamanetworkopen.2021.28204","volume":"4","author":"J Jankovic","year":"2021","unstructured":"Jankovic J et al (2021) Safety and efficacy of flexible-dose deutetrabenazine in children and adolescents with Tourette syndrome: a randomized clinical trial. JAMA Netw Open 4(10):e2128204","journal-title":"JAMA Netw Open"},{"issue":"10","key":"7172_CR131","doi-asserted-by":"publisher","first-page":"e2129397","DOI":"10.1001\/jamanetworkopen.2021.29397","volume":"4","author":"B Coffey","year":"2021","unstructured":"Coffey B et al (2021) Efficacy and safety of fixed-dose deutetrabenazine in children and adolescents for tics associated with Tourette syndrome: a randomized clinical trial. JAMA Netw Open 4(10):e2129397","journal-title":"JAMA Netw Open"},{"issue":"1","key":"7172_CR132","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s00213-020-05712-8","volume":"238","author":"SC Britch","year":"2021","unstructured":"Britch SC, Babalonis S, Walsh SL (2021) Cannabidiol: pharmacology and therapeutic targets. Psychopharmacology (Berl) 238(1):9\u201328","journal-title":"Psychopharmacology (Berl)"},{"issue":"7570","key":"7172_CR133","doi-asserted-by":"publisher","first-page":"S10","DOI":"10.1038\/525S10a","volume":"525","author":"S Pain","year":"2015","unstructured":"Pain S (2015) A potted history. Nature 525(7570):S10\u2013S11","journal-title":"Nature"},{"issue":"6","key":"7172_CR134","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1097\/00004714-198812000-00021","volume":"8","author":"R Sandyk","year":"1988","unstructured":"Sandyk R, Awerbuch G (1988) Marijuana and Tourette\u2019s syndrome. J Clin Psychopharmacol 8(6):444\u2013445","journal-title":"J Clin Psychopharmacol"},{"issue":"6","key":"7172_CR135","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1111\/j.1600-0447.1998.tb10127.x","volume":"98","author":"KR M\u00fcller-Vahl","year":"1998","unstructured":"M\u00fcller-Vahl KR et al (1998) Cannabinoids: possible role in patho-physiology and therapy of Gilles de la Tourette syndrome. Acta Psychiatr Scand 98(6):502\u2013506","journal-title":"Acta Psychiatr Scand"},{"issue":"3","key":"7172_CR136","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1176\/ajp.156.3.495","volume":"156","author":"KR M\u00fcller-Vahl","year":"1999","unstructured":"M\u00fcller-Vahl KR et al (1999) Treatment of Tourette\u2019s syndrome with delta-9-tetrahydrocannabinol. Am J Psychiatry 156(3):495","journal-title":"Am J Psychiatry"},{"issue":"2","key":"7172_CR137","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1055\/s-2002-25028","volume":"35","author":"KR M\u00fcller-Vahl","year":"2002","unstructured":"M\u00fcller-Vahl KR et al (2002) Treatment of Tourette\u2019s syndrome with Delta 9-tetrahydrocannabinol (THC): a randomized crossover trial. Pharmacopsychiatry 35(2):57\u201361","journal-title":"Pharmacopsychiatry"},{"issue":"4","key":"7172_CR138","doi-asserted-by":"publisher","first-page":"459","DOI":"10.4088\/JCP.v64n0417","volume":"64","author":"KR M\u00fcller-Vahl","year":"2003","unstructured":"M\u00fcller-Vahl KR et al (2003) Delta 9-tetrahydrocannabinol (THC) is effective in the treatment of tics in Tourette syndrome: a 6-week randomized trial. J Clin Psychiatry 64(4):459\u2013465","journal-title":"J Clin Psychiatry"},{"issue":"12","key":"7172_CR139","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1016\/S2215-0366(19)30401-8","volume":"6","author":"N Black","year":"2019","unstructured":"Black N et al (2019) Cannabinoids for the treatment of mental disorders and symptoms of mental disorders: a systematic review and meta-analysis. The Lancet Psychiatry 6(12):995\u20131010","journal-title":"The Lancet Psychiatry"},{"key":"7172_CR140","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2020.575826","volume":"11","author":"E Jakubovski","year":"2020","unstructured":"Jakubovski E et al (2020) The CANNA-TICS study protocol: a randomized multi-center double-blind placebo controlled trial to demonstrate the efficacy and safety of nabiximols in the treatment of adults with chronic tic disorders. Front Psychiatry 11:575826","journal-title":"Front Psychiatry"},{"issue":"10","key":"7172_CR141","doi-asserted-by":"publisher","first-page":"2413","DOI":"10.1002\/mds.28681","volume":"36","author":"KR M\u00fcller-Vahl","year":"2021","unstructured":"M\u00fcller-Vahl KR et al (2021) Monoacylglycerol lipase inhibition in tourette syndrome: a 12-week, randomized, controlled study. Mov Disord 36(10):2413\u20132418","journal-title":"Mov Disord"},{"issue":"1","key":"7172_CR142","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.pharmthera.2014.05.004","volume":"144","author":"M Quik","year":"2014","unstructured":"Quik M et al (2014) Role for the nicotinic cholinergic system in movement disorders; therapeutic implications. Pharmacol Ther 144(1):50\u201359","journal-title":"Pharmacol Ther"},{"issue":"8585","key":"7172_CR143","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1016\/S0140-6736(88)91388-8","volume":"1","author":"PR Sanberg","year":"1988","unstructured":"Sanberg PR et al (1988) Nicotine gum and haloperidol in Tourette\u2019s syndrome. Lancet 1(8585):592","journal-title":"Lancet"},{"issue":"1","key":"7172_CR144","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/0753-3322(89)90186-8","volume":"43","author":"PR Sanberg","year":"1989","unstructured":"Sanberg PR et al (1989) Nicotine potentiates the effects of haloperidol in animals and in patients with Tourette syndrome. Biomed Pharmacother 43(1):19\u201323","journal-title":"Biomed Pharmacother"},{"issue":"6","key":"7172_CR145","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1176\/ajp.148.6.793","volume":"148","author":"BJ McConville","year":"1991","unstructured":"McConville BJ et al (1991) Nicotine potentiation of haloperidol in reducing tic frequency in Tourette\u2019s disorder. Am J Psychiatry 148(6):793\u2013794","journal-title":"Am J Psychiatry"},{"issue":"8","key":"7172_CR146","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1016\/0006-3223(92)90315-Q","volume":"31","author":"BJ McConville","year":"1992","unstructured":"McConville BJ et al (1992) The effects of nicotine plus haloperidol compared to nicotine only and placebo nicotine only in reducing tic severity and frequency in Tourette\u2019s disorder. Biol Psychiatry 31(8):832\u2013840","journal-title":"Biol Psychiatry"},{"issue":"8864","key":"7172_CR147","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/0140-6736(93)91392-Y","volume":"342","author":"AA Silver","year":"1993","unstructured":"Silver AA, Sanberg PR (1993) Transdermal nicotine patch and potentiation of haloperidol in Tourette\u2019s syndrome. Lancet 342(8864):182","journal-title":"Lancet"},{"issue":"8936","key":"7172_CR148","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1016\/S0140-6736(94)90388-3","volume":"344","author":"SM Dursun","year":"1994","unstructured":"Dursun SM et al (1994) Longlasting improvement of Tourette\u2019s syndrome with transdermal nicotine. Lancet 344(8936):1577","journal-title":"Lancet"},{"issue":"12","key":"7172_CR149","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1097\/00004583-199612000-00015","volume":"35","author":"AA Silver","year":"1996","unstructured":"Silver AA et al (1996) Case study: long-term potentiation of neuroleptics with transdermal nicotine in Tourette\u2019s syndrome. J Am Acad Child Adolesc Psychiatry 35(12):1631\u20131636","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"9","key":"7172_CR150","doi-asserted-by":"publisher","first-page":"707","DOI":"10.4088\/JCP.v62n0908","volume":"62","author":"AA Silver","year":"2001","unstructured":"Silver AA et al (2001) Transdermal nicotine and haloperidol in Tourette\u2019s disorder: a double-blind placebo-controlled study. J Clin Psychiatry 62(9):707\u2013714","journal-title":"J Clin Psychiatry"},{"issue":"2","key":"7172_CR151","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.eurpsy.2003.11.002","volume":"19","author":"AL Howson","year":"2004","unstructured":"Howson AL et al (2004) Clinical and attentional effects of acute nicotine treatment in Tourette\u2019s syndrome. Eur Psychiatry 19(2):102\u2013112","journal-title":"Eur Psychiatry"},{"issue":"9","key":"7172_CR152","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1097\/00004583-200109000-00020","volume":"40","author":"AA Silver","year":"2001","unstructured":"Silver AA et al (2001) Multicenter, double-blind, placebo-controlled study of mecamylamine monotherapy for Tourette\u2019s disorder. J Am Acad Child Adolesc Psychiatry 40(9):1103\u20131110","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"5","key":"7172_CR153","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1212\/WNL.56.5.605","volume":"56","author":"C Marras","year":"2001","unstructured":"Marras C et al (2001) Botulinum toxin for simple motor tics: a randomized, double-blind, controlled clinical trial. Neurology 56(5):605\u2013610","journal-title":"Neurology"},{"key":"7172_CR154","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1113\/jphysiol.1981.sp013838","volume":"317","author":"LC Sellin","year":"1981","unstructured":"Sellin LC, Thesleff S (1981) Pre- and post-synaptic actions of botulinum toxin at the rat neuromuscular junction. J Physiol 317:487\u2013495","journal-title":"J Physiol"},{"issue":"3","key":"7172_CR155","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1002\/mds.870090315","volume":"9","author":"J Jankovic","year":"1994","unstructured":"Jankovic J (1994) Botulinum toxin in the treatment of dystonic tics. Mov Disord 9(3):347\u2013349","journal-title":"Mov Disord"},{"issue":"8","key":"7172_CR156","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1001\/archneur.57.8.1190","volume":"57","author":"CH Kwak","year":"2000","unstructured":"Kwak CH, Hanna PA, Jankovic J (2000) Botulinum toxin in the treatment of tics. Arch Neurol 57(8):1190\u20131193","journal-title":"Arch Neurol"},{"issue":"4","key":"7172_CR157","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1007\/s13311-020-00914-6","volume":"17","author":"A Billnitzer","year":"2020","unstructured":"Billnitzer A, Jankovic J (2020) Current management of tics and tourette syndrome: behavioral, pharmacologic, and surgical treatments. Neurotherapeutics 17(4):1681\u20131693","journal-title":"Neurotherapeutics"}],"container-title":["Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-023-07172-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10072-023-07172-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-023-07172-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T02:06:46Z","timestamp":1707530806000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10072-023-07172-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,14]]},"references-count":157,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["7172"],"URL":"https:\/\/doi.org\/10.1007\/s10072-023-07172-2","relation":{},"ISSN":["1590-1874","1590-3478"],"issn-type":[{"value":"1590-1874","type":"print"},{"value":"1590-3478","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,14]]},"assertion":[{"value":"8 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 October 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}